Immunosuppressive mechanisms in glioblastoma

EK Nduom, M Weller, AB Heimberger - Neuro-oncology, 2015 - academic.oup.com
Neuro-oncology, 2015academic.oup.com
Despite maximal surgical and medical therapy, the treatment of glioblastoma remains a
seriously vexing problem, with median survival well under 2 years and few long-term
survivors. Targeted therapy has yet to produce significant advances in treatment of these
lesions in spite of advanced molecular characterization of glioblastoma and glioblastoma
cancer stem cells. Recently, immunotherapy has emerged as a promising mode for some of
the hardest to treat tumors, including metastatic melanoma. Although immunotherapy has …
Abstract
Despite maximal surgical and medical therapy, the treatment of glioblastoma remains a seriously vexing problem, with median survival well under 2 years and few long-term survivors. Targeted therapy has yet to produce significant advances in treatment of these lesions in spite of advanced molecular characterization of glioblastoma and glioblastoma cancer stem cells. Recently, immunotherapy has emerged as a promising mode for some of the hardest to treat tumors, including metastatic melanoma. Although immunotherapy has been evaluated in glioblastoma in the past with limited success, better understanding of the failures of these therapies could lead to more successful treatments in the future. Furthermore, there is a persistent challenge for the use of immune therapy to treat glioblastoma secondary to the existence of redundant mechanisms of tumor-mediated immune suppression. Here we will address these mechanisms of immunosuppression in glioblastoma and therapeutic approaches.
Oxford University Press